文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

术后立体定向放射外科治疗切除性脑转移瘤:单中心逾500个瘤腔经验

Stereotactic Radiosurgery for Resected Brain Metastases: Single-Institutional Experience of Over 500 Cavities.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-11-27

该单中心回顾性研究纳入2007至2018年间442例患者共501个切除性脑转移瘤腔,评估术后立体定向放射外科(SRS)的疗效、毒性及失败模式。结果显示12个月局部失败率7%、不良放射效应9%、远隔颅内失败44%、软脑膜病变13%,总体软脑膜病变发生率15.8%,其中经典软脑膜病变生存更短且神经性死亡比例更高。

要点

  • 术后SRS局部控制好、毒性低,12个月局部失败率仅7%。
  • 颅内失败以远隔为主,12个月远隔颅内失败率达44%。
  • 经典软脑膜病变生存2.0个月,神经性死亡比例67%。

核心结论

  • 术后SRS治疗切除性脑转移瘤局部控制好、毒性低,颅内失败以远隔为主,软脑膜病变发生率上升。

研究设计与样本

  • 单中心回顾性研究,2007至2018年442例患者501个切除性脑转移瘤腔,共475次SRS疗程。

主要发现

  • SRS后中位临床随访10.1个月,中位总生存13.9个月(95%CI 11.8-15.2个月)。
  • 12个月局部失败率7%(95%CI 5%-10%),不良放射效应9%(95%CI 7%-12%)。
  • 12个月远隔颅内失败率44%(95%CI 40%-49%),远隔脑实质失败37%(95%CI 33%-42%),软脑膜病变13%(95%CI 10%-17%)。
  • 软脑膜病变总体发生率15.8%,其中经典软脑膜病变占53%、结节型占46%。
  • 经典软脑膜病变较结节型生存更短(2.0 vs 11.2个月,P<.01),神经性死亡比例更高(67% vs 41%,P=.02)。

关键数值与推荐

  • 12个月局部失败率7%(95%CI 5%-10%)。
  • 12个月不良放射效应发生率9%(95%CI 7%-12%)。
  • 12个月远隔颅内失败率44%(95%CI 40%-49%)。
  • 软脑膜病变总体发生率15.8%,经典型较结节型生存更短(2.0 vs 11.2个月,P<.01)。

临床怎么用

  • 术后SRS可作为切除性脑转移瘤的选择,局部控制好且毒性低。
  • 需关注远隔颅内失败和软脑膜病变,尤其经典软脑膜病变预后差。
  • 15%患者最终接受全脑放疗(WBRT)。

局限性

  • 单中心回顾性研究,术后SRS技术未标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Postoperative stereotactic radiosurgery (SRS) has less detrimental effect on cognition and quality of life compared with whole brain radiation therapy (WBRT) and is increasingly used for resected brain metastases (BMs). Postoperative SRS techniques are not standardized, and there is a concern for a different pattern of failure after postoperative SRS compared with WBRT. We aim to study the efficacy, toxicity, and failure pattern of postoperative SRS. METHODS AND MATERIALS: We retrospectively reviewed outcomes of patients with resected BMs treated with postoperative SRS between 2007 and 2018. Overall survival and cumulative incidences of local failure, overall distant intracranial failure (distant parenchymal failure, nodular leptomeningeal disease [nLMD], classical leptomeningeal disease [cLMD]), and adverse radiation effect were reported. Neurologic death was determined for patients with leptomeningeal disease (LMD). RESULTS: A total of 442 patients with 501 resected BMs were treated over 475 total SRS courses. Median clinical follow-up and overall survival after SRS were 10.1 months (interquartile range, 3.6-20.7 months) and 13.9 months (95% confidence interval [CI], 11.8-15.2 months), respectively. At 12 months, event rates were 7% (95% CI, 5%-10%) for local failure, 9% (95% CI, 7%-12%) for adverse radiation effect, 44% (95% CI, 40%-49%) for overall distant intracranial failure, 37% (95% CI, 33%-42%) for distant parenchymal failure, and 13% (95% CI, 10%-17%) for LMD. The overall incidence of LMD was 15.8% (53% cLMD, 46% nLMD). cLMD was associated with shorter survival than nLMD (2.0 vs 11.2 months, P < .01) and a higher proportion of neurologic death (67% vs 41%, P = .02). A total of 15% of patients ultimately received WBRT. CONCLUSIONS: We report the largest clinical experience of postoperative SRS for resected BMs, showing excellent local control and low toxicity. Intracranial failure was predominantly distant, with a rising incidence of LMD.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Shi S, Sandhu N, Jin MC, et al. Stereotactic Radiosurgery for Resected Brain Metastases: Single-Institutional Experience of Over 500 Cavities. Int J Radiat Oncol Biol Phys. 2019. PMID: 31785338. doi:10.1016/j.ijrobp.2019.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。